Vistagen Therapeutics, Inc. (VTGN) Stock Price & Analysis
Vistagen Therapeutics, Inc. (VTGN) rose 0.11% to USD 0.54 as of June 10, 2026 at 04:37 UTC, according to Nexqual real-time market data.
VTGN last closed at USD 0.54; the session ranged USD 0.52–0.57 on volume of 474,571 shares. Market capitalization is $21.31M, with a 52-week range of USD 0.43–5.14 (NCM). Source: Nexqual, June 10, 2026 at 04:37 UTC.
Key Statistics (as of June 10, 2026 at 04:37 UTC)
| Price | USD 0.54 |
|---|---|
| Change | ▲ 0.11% (up) |
| Previous Close | USD 0.54 |
| Open | USD 0.54 |
| Day Range | USD 0.52 – 0.57 |
| 52-Week Range | USD 0.43 – 5.14 |
| Volume | 474,571 shares |
| Market Cap | $21.31M |
| Exchange | NCM |
Technical Analysis (VTGN)
Nexqual's technical model rates VTGN "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:37 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.79 (neutral) |
| vs SMA50 | Below (USD 0.6) |
| MACD | -0.01 (negative) |
Analyst Ratings (VTGN)
Wall Street analysts rate VTGN "None" based on 3 analysts, with a mean price target of USD 0.97 (range USD 0.9–1), per Nexqual as of June 10, 2026 at 04:37 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 0.97 |
| High Target | USD 1 |
| Low Target | USD 0.9 |
| Buy / Hold / Sell | 0 / 5 / 0 |
Earnings (VTGN)
| EPS Estimate | USD -0.27 |
|---|---|
| Revenue Estimate | $275,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.45 vs est -0.49 ▲ beat |
| 2025-09-30 | USD -0.54 vs est -0.44 ▼ miss |
| 2025-06-30 | USD -0.47 vs est -0.44 ▼ miss |
| 2025-03-31 | USD -0.44 vs est -0.49 ▲ beat |
Source: Nexqual, June 10, 2026 at 04:37 UTC.
Financials & Fundamentals (VTGN)
| Total Revenue | $789,000 |
|---|---|
| Revenue Growth (YoY) | +29.50% |
| Gross Margin | +100.00% |
| Operating Margin | -6450.83% |
| Profit Margin | +0.00% |
| ROE | -101.55% |
| Debt / Equity | 2.8 |
| Current Ratio | 4.68 |
| Total Cash | $61.77M |
| Total Debt | $1.43M |
| Free Cash Flow | $-36.17M |
Source: Nexqual, June 10, 2026 at 04:37 UTC.
Financial Health Score (VTGN)
Nexqual rates Vistagen Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 04:37 UTC.
| Growth | Critical — Revenue -54% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $62M cash vs $1M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$36M, burning cash |
| Efficiency | Critical — ROE -102%, ROA -55.5% |
Ownership (VTGN)
| Insider Ownership | +0.27% |
|---|---|
| Institutional Ownership | +42.26% |
| Shares Outstanding | 39.62M |
| Float | 34.38M |
| Short % of Float | +7.27% |
Source: Nexqual, June 10, 2026 at 04:37 UTC.
Leadership (VTGN)
Vistagen Therapeutics, Inc. is led by Joshua S. Prince (age 54), Chief Operating Officer, per Nexqual as of June 10, 2026 at 04:37 UTC.
| Chief Operating Officer | Joshua S. Prince (age 54) |
|---|---|
| CFO, Principal Financial & Accounting Officer and Treasurer | Nick B. Tressler (age 52) |
| Senior Vice President of Investor Relations | Mark Adrian McPartland (age 59) |
| Vice President of Communications | Michelle Peters Wellington |
Major Backers & Investors (VTGN)
Notable institutional backers of Vistagen Therapeutics, Inc. include Orbimed Advisors LLC., TCG Crossover Management, LLC, Adar1 Capital Management, LLC , according to Nexqual as of June 10, 2026 at 04:37 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Orbimed Advisors LLC. | 7.72% |
| TCG Crossover Management, LLC | 6.76% |
| Adar1 Capital Management, LLC | 1.9% |
| Stempoint Capital LP | 1.56% |
| Acadian Asset Management. LLC | 1.49% |
| Ikarian Capital, LLC | 1.31% |
| Two Sigma Investments, LP | 1.19% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.94% |
| BlackRock | 1.38% |
| Geode Capital | 1.14% |
Source: Nexqual, June 10, 2026 at 04:37 UTC.
From Vistagen Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2025-06-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders.
- The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder.
- In addition, the company's clinical-stage pipeline consists of intranasal product candidates comprising pherines.
- It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VTVT | vTv Therapeutics Inc. | USD 31.77 | ▼ 1.15% |
| OTLK | Outlook Therapeutics, Inc. | USD 0.71 | ▼ 9.27% |
| TENX | Tenax Therapeutics, Inc. | USD 10.73 | ▲ 0% |
| VSTM | Verastem, Inc. | USD 3.82 | ▲ 2.96% |
| XBIO | Xenetic Biosciences, Inc. | USD 3.08 | ▼ 0.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:37 UTC. This page is informational and not investment advice.